Regeneron Pharmaceuticals, Inc. (REGN)
Automate Your Wheel Strategy on REGN
With Tiblio's Option Bot, you can configure your own wheel strategy including REGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol REGN
- Rev/Share 135.2445
- Book/Share 284.8611
- PB 2.0292
- Debt/Equity 0.0904
- CurrentRatio 4.5976
- ROIC 0.1047
- MktCap 60215639603.0
- FreeCF/Share 36.5804
- PFCF 15.6624
- PE 13.626
- Debt/Assets 0.0708
- DivYield 0.0046
- ROE 0.1511
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | REGN | Rothschild & Co Redburn | -- | Buy | -- | $890 | Aug. 14, 2025 |
| Downgrade | REGN | Argus | Buy | Hold | -- | -- | June 30, 2025 |
| Downgrade | REGN | Wells Fargo | Overweight | Equal Weight | -- | $580 | May 30, 2025 |
| Downgrade | REGN | RBC Capital Mkts | Outperform | Sector Perform | -- | $662 | May 30, 2025 |
| Upgrade | REGN | Citigroup | Neutral | Buy | -- | $700 | May 14, 2025 |
| Resumed | REGN | Cantor Fitzgerald | -- | Overweight | -- | $695 | April 22, 2025 |
| Upgrade | REGN | Leerink Partners | Market Perform | Outperform | $762 | $834 | Feb. 5, 2025 |
| Downgrade | REGN | UBS | Buy | Neutral | $1130 | $738 | Jan. 16, 2025 |
| Resumed | REGN | BofA Securities | -- | Underperform | -- | $565 | Dec. 10, 2024 |
| Downgrade | REGN | Leerink Partners | Outperform | Market Perform | $1175 | $1077 | Sept. 24, 2024 |
News
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss
Published: October 13, 2025 by: Zacks Investment Research
Sentiment: Neutral
Regeneron's DB-OTO gene therapy shows hearing gains in nearly all CHORD study participants, with durable and meaningful improvements.
Read More
Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Positive
REGN secures FDA approval to expand Libtayo's label for high-risk skin cancer, boosting its oncology momentum amid Eylea sales pressure.
Read More
Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
Published: October 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p
Read More
My Top 5 Biotech Stocks Big Pharma Could Buy Next
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
Regeneron Pharmaceuticals catalysts could drive stock higher: analysts
Published: October 03, 2025 by: Proactive Investors
Sentiment: Positive
JP Morgan analysts see an “attractive setup” for Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares, believing the company's Dupixent and Eylea drugs and cash on hand alone support valuation at current levels. In a note to clients on Friday, the analysts wrote that they expect several catalysts for the company over the next three to six months, including Phase 3 trial results for LAG3 melanoma treatment as well as several potential Eylea updates.
Read More
Final Trades: Nvidia, Amphenol, Regeneron and Lockheed Martin
Published: September 30, 2025 by: CNBC Television
Sentiment: Neutral
CNBC's "Halftime Report" team detail their stock picks and final trades.
Read More
FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza
Published: September 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Regeneron wins FDA approval to extend Evkeeza use in children as young as one with severe familial hypercholesterolemia.
Read More
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript
Published: September 24, 2025 by: Seeking Alpha
Sentiment: Neutral
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 24, 2025 10:30 AM EDT Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Christopher Fenimore - Executive VP of Finance & CFO Conference Call Participants William Pickering - Sanford C. Bernstein & Co., LLC.
Read More
SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU
Published: September 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Sanofi/Regeneron's Dupixent wins CHMP backing for chronic spontaneous urticaria in the EU, paving the way for expanded treatment options.
Read More
Regeneron says blood cancer therapy shows 100% response rate in precancerous disorder study
Published: September 19, 2025 by: Reuters
Sentiment: Positive
Regeneron said on Friday its experimental therapy showed either a complete or partial disappearance of a precancerous disorder, which manifests into blood cancer, in all patients in a mid-stage trial.
Read More
Regeneron's bone disorder treatment succeeds in late-stage trial
Published: September 17, 2025 by: Reuters
Sentiment: Positive
Regeneron Pharmaceuticals said on Wednesday its experimental treatment for a rare genetic disorder that affects bone tissue has met the main goal of a late-stage trial.
Read More
Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation
Published: September 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
FOP is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitation
Read More
REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Negative
Regeneron shares slump as Eylea struggles, but Dupixent gains and a strengthening oncology pipeline offer growth potential.
Read More
Regeneron Pharmaceuticals, Inc. (REGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Published: September 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:00 AM EDT Company Participants Christopher Fenimore - Executive VP of Finance & CFO Leonard Schleifer - Co-Founder, President, CEO & Co-Chairman Marion McCourt - Executive Vice President of Commercial Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Good morning, everybody.
Read More
What's Happening With Regeneron Pharmaceuticals Stock On Monday?
Published: September 08, 2025 by: Benzinga
Sentiment: Positive
Regeneron Pharmaceuticals, Inc. REGN revealed data from Phase 3 trials in adults with moderate-to-severe cat or birch allergies on Monday. Both trials met their respective primary and key secondary endpoints.
Read More
A new pharma factory shows how hard it could be for drugmakers to outrun Trump's tariffs
Published: August 21, 2025 by: CNBC
Sentiment: Positive
Fujifilm Biotechnologies will open a new biologics manufacturing plant in the U.S. this fall, with Regeneron and Johnson & Johnson as the initial customers. The Holly Springs, North Carolina, site is five years and $3.2 billion in the making.
Read More
FDA Extends Review Period of REGN's Submission for Eylea HD
Published: August 21, 2025 by: Zacks Investment Research
Sentiment: Neutral
The FDA extends action dates for Regeneron's Eylea HD filings following inspection findings at Catalent Indiana. Nonetheless, Eylea HD remains available through vial administration.
Read More
EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension
Published: August 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
TARRYTOWN, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD® (aflibercept) Injection 8 mg regulatory submissions. This includes a Chemistry, Manufacturing and Controls (CMC) Prior-Approval Supplement (PAS) for the EYLEA HD prefilled syringe and a supplemental Biologics License Application (sBLA) seeking approval for both the treatment of macular edema following retinal vein occlusion (RVO) and the broadening of the dosing schedule to include every 4-week (monthly) dosing across approved indications.
Read More
Can Eylea HD and Dupixent Profits Revive Regeneron Stock?
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Positive
REGN banks on Dupixent and Eylea HD gains to offset Eylea's decline while oncology wins strengthen its diversified pipeline.
Read More
Regeneron: EYLEA's Decline Is Masking A Deep Value Opportunity
Published: August 11, 2025 by: Seeking Alpha
Sentiment: Positive
Regeneron's Q2 showed strong earnings and cash flow, driven by DUPIXENT's growth and operational discipline, despite EYLEA's ongoing revenue decline. EYLEA faces intense competition and margin pressure, but DUPIXENT's expanding indications and LIBTAYO's solid performance offset these headwinds. Regeneron's oncology pipeline is advancing, highlighted by LYNOZYFIC's approval, while strategic moves in obesity drugs aim for future growth.
Read More
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2025 Earnings Call Transcript
Published: August 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q2 2025 Earnings Conference Call August 1, 2025 8:30 AM ET Company Participants Christopher R. Fenimore - Executive VP of Finance & CFO George D.
Read More
Nonfarm Payrolls Come in SIgnificantly Below Expectations
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Nonfarm Payrolls Come in SIgnificantly Below Expectations.
Read More
Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Positive
REGN stock up as Q2 EPS jumps 12% on strong Eylea HD and Dupixent profits, beating revenue and earnings estimates.
Read More
Regeneron (REGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Unlocking Q2 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Besides Wall Street's top-and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Read More
5 Stocks That Launched New Dividends In This Roller-Coaster Market
Published: July 29, 2025 by: Forbes
Sentiment: Positive
Brand new dividends are often the best divvies to buy. Here why.
Read More
Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Strong Dupixent profits and rising Eylea HD demand may help Regeneron offset pressure in its Q2 earnings report.
Read More
Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold?
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Negative
Eylea's sales slump and pipeline setbacks have dragged REGN down 22.8% YTD, underperforming its peers and the S&P 500.
Read More
About Regeneron Pharmaceuticals, Inc. (REGN)
- IPO Date 1991-04-02
- Website https://www.regeneron.com
- Industry Biotechnology
- CEO Leonard S. Schleifer
- Employees 15158